NEW YORK, NY / ACCESSWIRE / November 3, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Aurora Cannabis Inc. (NYSE:ACB)

CONTACT JAKUBOWITZ ABOUT ACB:
https://claimyourloss.com/securities/aurora-cannabis-inc-loss-submission-form/?id=10688&from=1

Class Period: February 13, 2020 - September 4, 2020

Lead Plaintiff Deadline: December 1, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (ii) the Company's purported "business transformation plan" and cost reset failed to mitigate the foregoing issues; (iii) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Raytheon Technologies Corporation (NYSE:RTX)

CONTACT JAKUBOWITZ ABOUT RTX:
https://claimyourloss.com/securities/raytheon-technologies-corporation-loss-submission-form/?id=10688&from=1

Class Period: February 10, 2016 - October 27, 2020

Lead Plaintiff Deadline: December 29, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and inadequate internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon Company's Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Zosano Pharma Corporation (NASDAQ:ZSAN)